Top healthcare stocks to explore in June: JNJ, LLY, ABBV, MRK & BMY

Highlights:

• Johnson & Johnson (NYSE: JNJ) revenue increased by 5% YoY in Q1, FY22.
• Merck & Company, Inc. (NYSE: MRK) revenue rose 50% YoY in Q1, FY22.
• Bristol-Myers Squibb Company (NYSE: BMY) stock returned over 21% gains YTD.

The US healthcare segment is one of the largest economic sectors comprising firms selling prescription drugs, medical devices, insurance, and hospital services. The industry saw strong growth during the pandemic driven by Covid-19 vaccine sales. Companies capitalized on the demand for covid drugs, medical devices, and testing services.

Now the Monkeypox cases have again turned the focus on the industry. Monkeypox cases were reported from California's Los Angeles and San Francisco areas. It could offer another opportunity for the healthcare sector to rise to the occasion and provide services to contain the disease.

Here we explore some of the top healthcare stocks to explore in June.

Also Read: Why is Polymath (POLY) crypto rising? know price & performance

Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson is a pharmaceutical company specializing in products like baby care, oral care, women's health, etc. It is based in New Brunswick, New Jersey.

The shares of the company traded at US$177.175 at 12:47 pm ET on June 7, up 0.44% from their closing price of June 6. Its stock value increased by 2.83% YTD.

The firm has a market cap of US$465.36 billion, a P/E ratio of 23.83, and a forward one-year P/E ratio of 17.24. Its EPS is US$7.42. The 52-week highest and lowest stock prices were US$186.69 and US$155.72, respectively. Its trading volume was 5,386,517 on June 6.

The company reported sales of US$23.4 billion in the first quarter of fiscal 2022, representing an increase of 5% YoY. Its net earnings came in at US$5.14 billion, or US$1.93 per diluted share, against an income of US$6.19 billion, or US$2.32 per diluted share, in Q1, FY21.

Also Read: How is Ethereum (ETH) crypto performing amid a market downturn?

Source: Pixabay

Image Description: Top healthcare stocks to explore in June

Eli Lilly and Company (NYSE: LLY)

Eli Lilly is one of the leading pharmaceutical firms based in Indianapolis, Indiana. It manufactures and supplies pharmaceutical products globally.

The stock traded at US$306.98 at 12:52 pm ET on June 7, up 1.19% from its previous closing price. The LLY stock rose 11.64% YTD.

The market cap of the company is US$292.29 billion, the P/E ratio is 45.57, and the forward one-year P/E ratio is 36.73. Its EPS is US$6.75.

The stock touched a peak price of US$324.08 and the lowest price of US$201.83 in the last 52 weeks. Its share volume on June 6 was 3,734,398.

The company's revenue increased by 15% YoY to US$7.81 billion in Q1, FY22. It reported a net income of US$1.90 billion, or US$2.10 per share, against an income of US$1.35 billion, or US$1.49 per share, in Q1, FY21.

Also Read: Why Saitama (SAITAMA) crypto fell? Is it worth exploring?

AbbVie Inc. (NYSE: ABBV)

AbbVie is a research-based biotechnology company based in North Chicago, Illinois. It specializes in developing drugs and therapies for immunology and oncology-related problems.

The shares of the company traded at US$147.49 at 1:13 pm ET on June 7, up 0.66% from their closing price of June 6. Its stock value surged 8.2% YTD.

The firm has a market cap of US$260.56 billion, a P/E ratio of 21.15, and a forward one-year P/E ratio of 10.43. Its EPS is US$6.97. The 52-week highest and lowest stock prices were US$175.91 and US$105.56, respectively. Its trading volume was 3,912,363 on June 6.

The company's worldwide net revenue increased by 4.1% YoY to US$13.53 billion in Q1, FY22. Its net earnings were US$4.49 billion, or US$2.51 per diluted share, as compared to earnings of US$3.55 billion, or US$1.99 per diluted share, in Q1, FY21.

Also Read: Will Target Corp (TGT) stock rebound after right-sizing inventory?

Merck & Company, Inc. (NYSE: MRK)

Merck & Co. is a global healthcare and pharmaceutical company based in Whitehouse Station, New Jersey. It provides medicines and other related products for humans and animals.

Its stock closed at US$90.48 on June 7, up 0.71% from its previous close. The MRK stock gained 16.87% YTD.

The market cap of the company is US$228.80 billion, the P/E ratio is 16.19, and the forward one-year P/E ratio is 12.29. Its EPS is US$5.59. The stock touched a peak price of US$94.92 and the lowest price of US$15.32 in the last 52 weeks. Its share volume on June 6 was 8,336,893.

On May 24, Merck announced that its board of directors declared a quarterly dividend of US$0.69 on each common stock for Q3, FY22.

In the first quarter of fiscal 2022, the company's total sales surged 50% YoY to US$15.9 billion. Its GAAP net income came in at US$4.31 billion, or US$1.70 per share, compared to US$2.74 billion, or US$1.08 per share, in Q1, FY21.

Also Read: US narrows record trade deficit as imports shrink 3.4% in April

Bristol-Myers Squibb Company (NYSE: BMY)

Bristol-Myers Squibb is a biopharmaceutical firm specializing in a range of biopharmaceutical products. It is based in New York.

The shares of the company closed at US$76.59 on June 7, up 1.78% from their closing price of June 6. Its stock value increased by 21.61% YTD.

The firm has a market cap of US$163.06 billion, a P/E ratio of 27.16, and a forward one-year P/E ratio of 9.97. Its EPS is US$2.82. The 52-week highest and lowest stock prices were US$78.61 and US$53.22, respectively. Its trading volume was 11,551,280 on June 6.

The company reported revenue of US$11.64 billion in Q1, FY22, up 5% from US$11.07 billion in the year-ago quarter. Its net earnings were US$1.28 billion, or US$0.59 per diluted share, compared to US$2.02 billion, or US$0.89 per diluted share, in Q1, FY21.

Also Read: Kohl’s Corp mulls US$8-bn buyout offer from Franchise Group

Bottom Line:

This year, healthcare stocks have retreated amid a decline in the broader market, stung by various negative macroeconomic and geopolitical factors. The healthcare sector of the S&P 500 fell 8.12% YTD and is up 6.30% over the past 12 months. Hence, investors should evaluate the companies and the market closely before investing in stocks.